Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
77°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fate Therapeutics
(NQ:
FATE
)
3.840
+0.070 (+1.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fate Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
Dow Rises Over 300 Points; US Adds 223,000 Jobs In December
January 06, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
January 06, 2023
Via
Benzinga
What 6 Analyst Ratings Have To Say About Fate Therapeutics
January 05, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 06, 2023
Via
Benzinga
Amarin To Rally 138%? Here Are 10 Other Analyst Forecasts For Friday
January 06, 2023
Via
Benzinga
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
January 06, 2023
Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
January 06, 2023
The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
January 05, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Cathie Wood Can't Keep Hands Off Tesla As Holiday Season Binge Grows To Nearly Half A Million Shares
January 04, 2023
Cathie Wood-led ARK Investment Management bought 21,050 shares of Tesla Inc (NASDAQ: TSLA) on Wednesday at an estimated valuation of over $2.39 million.
Via
Benzinga
Alibaba, XPeng, Dada Nexus And Some Other Big Stocks Moving Higher On Wednesday
January 04, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Cathie Wood Loads Up Another $2M In Tesla While Elon Musk Urges Employees To Look Beyond Stock Plunge
December 28, 2022
As Tesla Inc (NASDAQ: TSLA) shares witnessed a surprise rebound on Wednesday, Cathie Wood-led ARK Investment Management
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
December 22, 2022
Via
Benzinga
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
December 13, 2022
Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence of iPSC-derived Cells in Preclinical Allogeneic Models
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
December 15, 2022
Via
Benzinga
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
December 12, 2022
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share.
Via
Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
December 12, 2022
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
December 12, 2022
From
GT Biopharma, Inc.
Via
GlobeNewswire
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
December 10, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
December 10, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 06, 2022
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.
Via
TheNewswire.com
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 06, 2022
By Ernest Dela Aglanu, Benzinga
Via
News Direct
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
November 07, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present at Upcoming Investor Conferences
November 04, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
November 03, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
November 03, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Preview: Fate Therapeutics's Earnings
November 02, 2022
Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Fate...
Via
Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
October 25, 2022
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.
Via
Benzinga
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
October 24, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting
October 05, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.